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Abstract
Background: Whilst current guidelines highlight the importance of pain management for children with acute otitis
media (AOM), there is evidence to suggest that this is not implemented in everyday practice. We have developed a
primary care-based multifaceted educational intervention to optimise pain management in children with AOM, and
we trial its clinical and cost effectiveness.
Methods: This cluster randomised controlled trial aims to recruit 250 children aged 6 months to 10 years
presenting with AOM to general practitioners (GPs) in 30 primary care centres (PCCs) across the Netherlands. GPs in
the PCCs allocated to the intervention group receive a blended GP educational programme (online and face-to-
face training). The intervention asks GPs to proactively discuss pain management with parents using an information
leaflet, and to prescribe paracetamol and ibuprofen according to current guidelines. GPs in both groups complete
an online module illustrating various otoscopic images to standardise AOM diagnosis. GPs in the PCCs allocated to
the control group do not receive any further training and provide ‘care as usual’.
During the 4-week follow-up, parents complete a symptom diary. The primary outcome is the difference in
parent-reported mean earache scores over the first 3 days. Secondary outcomes include both number of days
with earache and fever, GP re-consultations for AOM, antibiotic prescriptions, and costs. Analysis will be by
intention-to-treat.
Discussion: The optimal use of analgesics through the multifaceted intervention may provide symptom relief
and thereby reduce re-consultations and antibiotic prescriptions in children with AOM.
Trial registration: Netherlands Trial Register, NTR4920. Registered on 19 December 2014.
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Background
Analgesics are the cornerstone of childhood acute otitis
media (AOM) management. Optimal use of analgesics
provides symptom relief and has the potential to reduce
re-consultations, antibiotic prescription, and healthcare
costs. Current AOM practice guidelines therefore empha-
sise the importance of providing analgesics to all children
with AOM in an weight-appropriate dose, in addition to
prescribing antibiotics for certain children [1, 2].
In daily practice, little attention is paid to earache man-
agement during the medical consultation [3–6] and rou-
tine antibiotic prescription is still very common [3, 7, 8].
Key factors driving the management decisions of general
practitioners (GPs) include concerns from both clinicians
and parents about the vulnerability of young children and
parental pressure to prescribe antibiotics; parents believe
that antibiotics are the proper treatment for AOM and an-
algesics as a standalone treatment are generally considered
insufficient [9–11].
Multifaceted interventions addressing these concerns
from both the GP and parent perspective have proven
effective in changing clinical practice [12, 13] and are
highly valued by GPs [14]. We therefore developed a pri-
mary care-based multifaceted educational intervention
to optimise pain management in children with AOM
and we will trial its clinical and cost effectiveness.
Objective
We aim to establish the clinical and cost effectiveness of
a primary care-based multifaceted educational interven-
tion focused on optimising pain management in children
with AOM.
Methods and analysis
Design of the intervention to optimise pain management
in children with AOM
The Medical Research Council guidance for complex in-
terventions was used to develop our multifaceted inter-
vention [15]. The various elements of the intervention
were chosen based on a literature review, consultation
with clinical experts including a broad range of disciplines
such as GPs, an ear, nose, and throat (ENT) surgeon, and
a nurse specialist as well as educational experts, and a
qualitative pre-study with GPs and parents.
Following this multi-phase process, we found that multi-
faceted interventions including a GP educational
programme with condensed information of a clinical
guideline may impact GP prescribing [12, 13, 16, 17], and
allows for addressing parental factors influencing the man-
agement decisions of GPs [6, 11]. Individual online training
appeared to be more effective than face-to-face group work
[18], and the impact may increase when online training is
complemented by individual face-to-face visits to convey
feedback on performance in the training and to overcome
obstacles to change [19]. In addition, patient information
leaflets have the potential to impact GP prescribing and
guide parental management decisions [20, 21].
Our multifaceted intervention therefore comprises of
four core elements to educate GPs in different aspects
(knowledge, attitude, skills, and behaviour): i) an online
training module; ii) a face-to-face-meeting; iii) a parent
information leaflet; and iv) prescription of analgesics
(see Table 1).
Online training module
The online training module, which takes approximately
30 min to complete, educates GPs about pain manage-
ment in childhood AOM through a combination of
proven effective educational components such as
case-based learning [22], self-assessment with immediate
feedback [22], reflection [22], and video demonstrations
of effective communication techniques [13, 23]. GPs are
trained to proactively discuss pain management with
parents using the parent information leaflet and they are
prompted to prescribe both paracetamol and ibuprofen
according to current AOM guidelines [1, 24].
GP adherence to the online training module (i.e.
whether the GP completed the module), as well as indi-
vidual answers by GPs to the various questions, will be
automatically recorded in the digital Julius Center CME
platform. The full content of the module will be made
available at the trial website (www.pimpomstudie.nl)
after completion of the trial.
Face-to-face meeting
Upon completion of the online training module by GPs
in the intervention primary care centre (PCC), a
face-to-face meeting with the co-ordinating investigator
and the GPs will be scheduled at the GP’s PCC to ensure
engagement. This also provides an opportunity to dis-
cuss the main topics of the online training module (see
above and Table 1) and potential barriers and facilitators
to analgesic prescription.
Parent information leaflet
The parent information leaflet is illustrated in Additional
file 1; it explains the importance of adequate pain man-
agement and includes tables of weight-appropriate dos-
ing of paracetamol and ibuprofen based on prevailing
Dutch guidelines [1, 24]. The leaflet also debunks com-
mon myths and misconceptions about the use of analge-
sics in children [10, 11].
Prescription of analgesics
Despite paracetamol and ibuprofen being available
over-the-counter in the Netherlands, GPs in the interven-
tion group are requested to prescribe these drugs at a
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weight-appropriate dose [1, 24] and request parents to fill
these prescriptions at the local pharmacy the same day.
Randomised controlled trial of the intervention to
optimise pain management in children with AOM
Study design and setting
We designed a pragmatic, cluster randomised controlled
trial to assess the clinical and cost effectiveness of the
primary-care based multifaceted educational interven-
tion aimed at optimising pain management compared
with ‘care as usual’ in children with AOM. A SPIRIT
checklist is attached as Additional file 2, and the SPIRIT
figure (Fig. 1) shows the study design.
Approximately 30 general practices in multiple regions
across the Netherlands will participate and enrol chil-
dren to the trial. The trial recruitment period is 3 years
with a follow-up of individuals for 4 weeks. Participating
PCCs will be revisited every year in the autumn (prior to
the annual peak incidence of AOM) to refresh key ele-
ments of the intervention and study procedures.
Randomisation and blinding
The unit of randomisation is the PCC; participating
centres are randomly allocated to either the multifa-
ceted education intervention or the usual care group.
GPs in the same PCC will thus be allocated to the
same ‘treatment’ group to avoid contamination
issues.
A trial website has been designed to randomly as-
sign participating PCCs to either the intervention or
the control group. To ensure equal distribution of
PCC characteristics (size and age distribution) across
‘treatment’ groups, an independent statistician has de-
signed a computerised minimisation strategy with a
random component of 30% [25].
We will perform an open-label trial, in other words
no blinding will be performed. However, to avoid
contamination between intervention and control PCCs
during enrolment as much as possible, GPs in the
control group are asked to participate in a study to
monitor earache in children with AOM.
Table 1 Main topics in the blended learning module
Topic Intervention element Educational component Educational level
Otoscopy, including abnormal tympanic membrane
appearances (AOM, OME)
Online training module
(both intervention and control)
Case-based learning
Self-assessment with
immediate feedback (MC)
Knowledge
Skills
Prevalence and natural course of earache due to AOM Online training module Case-based learning
Self-assessment with
immediate feedback (MC)
Knowledge
(Limited) effect of antibiotics on AOM symptoms, including earache Online training module Case-based learning
Self-assessment with
immediate feedback (MC)
Knowledge
Safety and adverse effects of paracetamol and ibuprofen Online training module Case-based learning
Self-assessment with
immediate feedback (MC)
Knowledge
Parents’ beliefs, concerns, and expectations relating to
(earache due to) AOM and analgesics use
Online training module
Face-to-face training
Case-based learning
Open questions
Knowledge
GP barriers to prescribe paracetamol and/or ibuprofen Online training module
Face-to-face training
Open questions Knowledge
Attitude
Dosing and timing of analgesics according to the 2007 “Pain Relief”
guideline [24] (and subsequent 2014 “AOM in children” guideline [1])
Online training module
Face-to-face training
Information leaflet
Case-based learning
Self-assessment with
immediate feedback (MC)
Knowledge
Skills
How to use effective communication skills to address pain
management in a consultation
Online training module Video demonstration Skills
Use the three communication elements of an effective
consultation [13, 21]:
• explore beliefs, concerns and expectations of parents regarding
the use of analgesia
• stress the importance of analgesic treatment during the consultations
and agree with the parents on pain management
• check parents’ understanding
Online training module Video demonstration Behaviour
Attitude
Use a parent information leaflet during the consultation Face-to-face training
Information leaflet
Lecture/presentation Behaviour
Attitude
Prescribe paracetamol and ibuprofen Face-to-face training
Information leaflet
Lecture/presentation Behaviour
Attitude
AOM acute otitis media, GP general practitioner, MC multiple choice, OME otitis media with effusion
van Uum et al. Trials  (2018) 19:501 Page 3 of 9
To ensure standardised AOM diagnosis, each partici-
pating GP receives unique user credentials to access the
digital Julius Center CME platform containing an online
module illustrating various otoscopic images (i.e. normal
appearance of tympanic membrane, AOM, and otitis
media with effusion). GPs in the intervention PCCs re-
ceive additional access to the online training module.
Eligibility criteria
Children aged 6 months to 10 years presenting to their
GP with earache and AOM are eligible for inclusion.
Those with ventilation tubes in place are excluded, as
well as previously included children, those with a previ-
ously included sibling, and children with either Down’s
syndrome, craniofacial malformations, known immuno-
deficiencies, liver failure, or renal insufficiency.
Inclusion and baseline assessments
All participating GPs inform the parents of potentially eli-
gible children about the trial. After obtaining informed
consent, GPs complete a short questionnaire regarding the
child’s medical history (recurrent AOM, recurrent upper
respiratory tract infection, previous ENT surgery, and
atopy) and perform a short physical examination (presence
of fever and appearance of the tympanic membrane).
Participating GPs are also asked to complete
non-recruitment logs, documenting reasons for
Fig. 1 Overview and schedule of enrolment, data collection, and assessments (SPIRIT Figure). 1Baseline data includes age, gender, medical history,
day-care attendance, vaccination status, exposure to tobacco smoke, family composition, and items discussed by general practitioner (GP) during
acute otitis media (AOM) consultation. 2Symptoms include earache (on Wong-Baker Faces Scale rating), ear discharge, fever, runny nose, cough,
disturbed sleep, diarrhoea, obstipation, vomiting, decreased fluid intake, abdominal pain, and rash. 3Medication use includes specification of type
of medication, dosing frequency, actual dosage given, over-the-counter medication, (delayed) antibiotic prescription. 4Productivity loss is captured
as composite of number of days absence from work (parent) or day-care (child), number of hours a nanny was required, and costs of nanny
employment. 5Adverse events include gastrointestinal complaints, as well as serious adverse events such as renal failure, gastrointestinal bleeding,
and hypersensitivity reactions. 6GP re-consultation includes out-of-hours consultation and referral to secondary care (i.e. emergency room visits,
hospital admissions, and surgical procedures). PCC primary care centre
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non-recruitment of eligible patients and eligible patients
who declined to participate.
GPs in the intervention group will advise parents of
children on analgesics according to the instructions of
the multifaceted intervention (see above). Other clinical
decisions such as antibiotic prescriptions are at the dis-
cretion of the GP. Children in the control group will re-
ceive ‘care as usual’ and complete the same study
procedures as those in the intervention group.
Follow-up data collection
At inclusion, GPs provide parents with a study diary to re-
port various outcomes (see Fig. 1). Parents complete a
daily symptom diary for 2 consecutive weeks. At baseline,
and at 2 and 4 weeks, parents complete quality of life
questionnaires and, at 4 weeks, parents fill out a product-
ivity loss questionnaire. The study team will contact
parents by phone on day 3 to optimise parents’ compli-
ance and to capture critical data on our primary outcome
(Fig. 1). One month after inclusion, the co-ordinating in-
vestigator will contact parents by telephone or email with
a reminder to return the completed diary by mail.
After 4 weeks, the coordinating investigator will visit
the PCC to retrieve the data of participating children
from their medical records (Fig. 1).
Validated questionnaires used
Parents report their child’s earache intensity using the
Wong-Baker FACES® Pain Rating Scale (scores range from
0 to 10, with lower scores indicating less pain) [26–29].
Disease-specific quality of life of the child is assessed at
baseline and at 4 weeks with the parent-reported Otitis
Media-6 (OM-6), a six-item questionnaire recording
ear-related problems (scores range from 6 to 42, with
lower scores indicating better quality of life) [30]. Quality
of life of the parents is assessed at baseline and at 2 weeks
with the EuroQOL five dimensions quality of life ques-
tionnaire (EQ-5D) [31], and productivity losses are
assessed with an adapted version of the iMTA Productivity
Cost Questionnaire (iPCQ) [32].
Primary and secondary outcomes
The primary outcome of interest is the difference in
parent-reported mean earache score over the first 3 days.
Secondary outcomes are the number of days with earache
and earache severity, number of days with fever, the pro-
portion of children with earache at various time points
(24 h, 2 to 3 days, 4 to 7 days), GP re-consultation because
of AOM, antibiotic prescriptions because of AOM,
health-related quality of life (HRQoL) of the child and
their parents, working days lost for the parents, days lost
from day-care or school for children, complications of
AOM, (serious) adverse events of analgesics, healthcare
use, and cost effectiveness.
Sample size calculation
In a previous childhood AOM trial, the mean earache
score on days 1 to 3 was 3.7 (standard deviation 2.57)
[33]. We consider a 25% reduction of this mean earache
score clinically relevant. With 80% power, at a 5% signifi-
cance level, a minimum of 66 children per group is
needed. The inflation factor for the cluster design is 1.7
assuming an intra-class correlation coefficient of 0.05
(for PCC level) [34, 35] and a cluster size of 15 children
(anticipating that not all PCCs recruit children to the
trial). As such, the number of children that need to be
included per group will be 115. Based on previous ex-
perience, we consider a loss to follow-up of 10% to be
reasonable [36, 37], and therefore aim to include 125
children per group (250 children in total).
Statistical analysis
Analysis will be performed according to the intention
-to-treat principle.
Clinical effectiveness For our primary outcome, we will
calculate the effect of the multifaceted intervention on
parent-reported mean earache score over the first 3 days
using a linear mixed model. A random intercept for
PCC will be included in the model to account for cluster
randomisation and a residual covariance (i.e. generalised
estimating equation type) matrix will be included for re-
peated measurements (days 1, 2, and 3 after the initial
GP visit). Clustering is estimated with an intra-class cor-
relation. Treatment effects will be reported as the crude
and adjusted difference in mean earache scores over the
first 3 days between study groups with accompanying
95% confidence intervals. We plan to adjust for baseline
differences in pre-specified confounders [38], including
age, gender, ill appearance, fever, history of recurrent
AOM, antibiotic use, and day-care attendance. Missing
data at baseline will be imputed using the multivariate
imputation by chained equations (MICE) procedure
[39]. The imputed data sets will be analysed, and results
combined. We will average estimates of the treatment
effects to give a single mean estimate and adjusted
standard errors according to Rubin’s rule [40]. In pri-
mary analysis, we will include all patients for whom the
outcome was observed. In a sensitivity analysis, or in
case of extensive missing data, we will impute missing
outcome data using the multiple imputation techniques
described above [41]. Where appropriate, we will also
perform an adherence-adjusted analysis.
For our secondary outcomes, we will use mixed logis-
tic regression analyses for dichotomous variables, and
mixed Poisson regression analyses for count variables. In
case of insufficient or non-events, for example very few
re-consultations, we will perform a simplified analysis
without adjustment for confounders and clustering.
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Cost-effectiveness analysis (CEA) We will take medical
and non-medical direct and indirect costs into account,
thus using a societal perspective for this analysis. All
analyses will use a time horizon of 4 weeks, correspond-
ing to the follow-up period in the study. Therefore, dis-
counting is not applicable.
We will use a Dutch database of current drug prices
(www.medicijnkosten.nl) to estimate costs of patient
drug use. These costs will be increased with a pharma-
cist’s charge. We will base the costs of over-the-counter
medication and complementary medication, if used, on
average retail prices. We will base the costs of consulting
a GP or a medical specialist, or other procedures and
hospitalisations, on current Dutch guidelines for
pharmaco-economic evaluation [42]. These guidelines
include reference cost figures for use in health economic
evaluations for common types of healthcare use. We ex-
tract resource use from the patient diaries. This includes
doctor visits, prescribed medication including antibi-
otics, specialist referrals, hospital admissions, and surgi-
cal interventions, as well as out-of-pocket expenses such
as over-the-counter medication, child care, and travel
costs. When no reference prices are available, we will cal-
culate cost prices according to guidelines for economic
evaluation in healthcare research [42]. Indirect costs to so-
ciety associated with absence from work will be estimated
using the friction cost method [43]. Overall costs will be
compared across the study groups and, where relevant, we
will calculate differences, including 95% confidence inter-
vals, using two-stage non-parametric bootstrap sampling
(of clusters and participants) [44].
In cost-effectiveness analysis, we will calculate incre-
mental cost-effectiveness ratios by dividing the estimated
differences in costs by the differences in effects observed,
i.e. the additional cost per point reduction in mean ear-
ache score on days 1 to 3, for the optimised pain manage-
ment strategy compared with the ‘usual care’ strategy.
We will address uncertainty by means of two-stage
non-parametric bootstrap sampling (of clusters and partici-
pants) [44]. We will use net benefit regression methods to
study the effect of any differences in baseline characteristics
and cluster differences on cost-effectiveness results. We will
compare the results of the two-stage bootstrap sampling
and the multilevel net benefit regression methods to assess
robustness of the cost-effectiveness estimates. We will
present the final results using incremental cost-effectiveness
planes and cost-effectiveness acceptability curves.
Process evaluation: understanding change processes
During the recruitment phase, we will perform two
qualitative studies as process evaluations alongside our
trial to unravel mechanisms by which the multifaceted
intervention may sort its effects [45–47]. In both studies
we will use semi-structured interviews, which are
audio-recorded and transcribed verbatim. Interviews will
be analysed thematically using a grounded theory ap-
proach by all members of the multidisciplinary research
team, including a primary healthcare sociologist, an
ENT surgeon, an educational specialist, and academic
GPs. We expect to reach saturation after 10–20 inter-
views in each study based on previous research [11, 48].
In one qualitative study, we will interview a subset of
GPs in the intervention PCCs using purposeful sam-
pling. In these interviews, the views and expectations of
GPs on analgesia and how the multifaceted educational
intervention shaped these perceptions will be explored.
In a second qualitative study, we will perform interviews
with parents from both the intervention and control
groups to investigate their perceptions towards earache,
AOM, and its management (with a specific focus on anal-
gesia), and their experiences with AOM-related doctor
consultations in general and the baseline study visit in par-
ticular. The results of these process evaluations will facili-
tate the interpretation of trial results. We also plan to
conduct a further evaluation according to Kirkpatrick’s
evaluation model [49] (see Table 2) which may aid future
implementation of the intervention.
Implementation of the multifaceted intervention
The results of this research project will be disseminated
through publications in peer-reviewed professional jour-
nals, and will be presented at national and international
conferences. If our intervention proves effective, we will li-
aise with all relevant stakeholders including GPs, parents
Table 2 Evaluation of the intervention according to Kirkpatrick’s model
Intervention Evaluation method Evaluated aspect
Online module Audio-recorded evaluation during the face-to-face visit with the coordinating investigator Reaction/satisfaction
Blended learning Questionnaire at baseline in the parental diary assessing whether analgesic treatment
was explicitly discussed during the consultation
Knowledge/behaviour
Parent information
leaflet
Questionnaire at baseline in the parental diary assessing whether the leaflet
• has been discussed during the consultation
• has been read by the parents and whether they found it useful
Knowledge/behaviour
Reaction/satisfaction
Prescription Questionnaire at baseline in the parental diary assessing whether the general
practitioner prescribed paracetamol and/or ibuprofen
Knowledge/behaviour
Combined intervention Audio-recorded evaluation during the close-out visit of the study Reaction/satisfaction
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of children with AOM, and the Dutch College of General
Practitioners (Nederlands Huisartsen Genootschap) to de-
velop a dissemination and implementation plan to ensure
rapid and effective dissemination and translation into clin-
ical practice.
Data management
Data monitoring
Although monitoring is not strictly necessary in the
Netherlands for studies to which the Dutch Medical Re-
search Involving Human Subjects Act (WMO) does not
apply, we will have our study monitored yearly by an inde-
pendent Data Monitoring Committee at the University
Medical Center Utrecht, in the shape of a low-risk research
data monitor, to ensure the quality of the trial execution.
Data deposition and curation
Each participant is assigned a unique study identification
number. This enables us to handle and store data in a
non-traceable manner within a secured and coded data-
base designed by the data management department of
the Julius Center. Paper-based data are automatically en-
tered on an online database (Research Online) which
our data management department develops and main-
tains. After termination of the study, the database will
become available to authorised persons (investigators,
monitors, auditors) only. We have not planned any in-
terim analyses.
Upon completion of the trial, data are stored for the at
least 15 years on a central drive of the data management
department of the Julius Center and will be made avail-
able for the use by third parties upon request and ap-
proval of the principal investigator (RAMJD).
Discussion
To our knowledge, this trial is unique in focusing on
optimising analgesia to reduce pain and antibiotic use in
childhood acute otitis media. The trial intervention has
been developed systematically in close collaboration with
educational and clinical experts and parents of children
with AOM. The trial will assess both clinical and cost ef-
fectiveness, as well as underlying mechanisms through
parallel process evaluations.
Even though the intervention is targeted at GPs, the
impact is measured at the patient level which potentially
underestimates the benefit of optimising pain manage-
ment. However, we deem an individually randomised,
placebo-controlled trial unethical since analgesics are
widely accepted as standard care in children with AOM.
Findings from the trial and parallel process evaluations
may contribute to optimisation of childhood AOM
management.
Trial status
The trial design has been registered prior to enrolment
on 19 December 2014 in a public trial registry
(Netherlands Trial Register, NTR4920). At the time of
submission of this manuscript, 218 patients have been
recruited into the trial.
Additional file
Additional file 1: Information leaflet about pain relief for children with
middle ear infection. (PDF 665 kb)
Additional file 2: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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